Valiant Laboratories (NSE:VALIANTLAB) Accounts Payable & Accrued Expense: ₹0 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:VALIANTLAB Valiant Laboratories Ltd NSE:VALIANTLAB
54 GF Score
Price ₹127.91
GF Value ₹149.77
Valuation Modestly Undervalued
! 8 Warning Signs
View Full Analysis

What is Valiant Laboratories Accounts Payable & Accrued Expense?

Valiant Laboratories NSE:VALIANTLAB +2.49% 54 Accounts Payable & Accrued Expense is ₹0 Mil as of Jun. 2026. GuruFocus rates NSE:VALIANTLAB with a GF Score™ of 54/100 and a GF Value™ of ₹149.77 (Modestly Undervalued). The stock has 8 warning signs investors should review.

Valiant Laboratories's quarterly accounts payable & accrued expense increased from Dec. 2025 (₹0 Mil) to Mar. 2026 (₹992 Mil) but then declined from Mar. 2026 (₹992 Mil) to Jun. 2026 (₹0 Mil).

Valiant Laboratories's annual accounts payable & accrued expense increased from Mar. 2024 (₹263 Mil) to Mar. 2025 (₹410 Mil) and increased from Mar. 2025 (₹410 Mil) to Mar. 2026 (₹992 Mil).

Valiant Laboratories Accounts Payable & Accrued Expense Historical Data

* Premium members only.

The historical data trend for Valiant Laboratories's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Valiant Laboratories Accounts Payable & Accrued Expense Chart

Valiant Laboratories Annual Data
Trend Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Accounts Payable & Accrued Expense
Get a 7-Day Free Trial 471.99 480.05 262.63 409.75 991.67

Valiant Laboratories Quarterly Data
Mar21 Mar22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Accounts Payable & Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 484.76 0.00 991.67 0.00
NSE:VALIANTLAB
54GF Score
Valiant Laboratories Ltd NSE:VALIANTLAB
Accounts Payable & Accrued Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Valiant Laboratories Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

What does a Accounts Payable & Accrued Expense of ₹0 Mil mean?
Valiant Laboratories (NSE:VALIANTLAB) has a Accounts Payable & Accrued Expense of ₹0 Mil as of Jun. 2026. Accounts payable and accrued expenses are amounts a company expects to pay to suppliers and others. View historical data on Valiant Laboratories and its competitors.
Is Valiant Laboratories' Accounts Payable & Accrued Expense too high?
Valiant Laboratories' current Accounts Payable & Accrued Expense is ₹0 Mil. Overall, Valiant Laboratories has a GF Score™ of 54/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Valiant Laboratories' Accounts Payable & Accrued Expense compare to ZTS?
Valiant Laboratories' Accounts Payable & Accrued Expense of ₹0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable & Accrued Expense for a Drug Manufacturers company?
A good Accounts Payable & Accrued Expense depends on the Drug Manufacturers industry context. However, Accounts Payable & Accrued Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable & Accrued Expense mean?
A high Accounts Payable & Accrued Expense can signal that a stock is expensive relative to its fundamentals. Accounts payable and accrued expenses are amounts a company expects to pay to suppliers and others. View historical data on Valiant Laboratories and its competitors. Valiant Laboratories's current Accounts Payable & Accrued Expense is ₹0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Valiant Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Valiant Laboratories (NSE:VALIANTLAB) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹149.77, compared to a current price of ₹127.91 — trading 14.6% below its estimated fair value. The current Accounts Payable & Accrued Expense is ₹0 Mil. Valiant Laboratories' overall GF Score™ is 54/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable & Accrued Expense calculated?
Accounts Payable & Accrued Expense is calculated from a company's financial statements. For Valiant Laboratories (NSE:VALIANTLAB), the current Accounts Payable & Accrued Expense is ₹0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Valiant Laboratories (NSE:VALIANTLAB) Overvalued in 2026?

Based on GuruFocus' analysis, Valiant Laboratories stock appears to be undervalued. The current stock price of ₹127.91 is trading 14.6% below its estimated GF Value™ of ₹149.77. GuruFocus considers Valiant Laboratories to be Modestly Undervalued.

Key valuation signals for NSE:VALIANTLAB:

  • Accounts Payable & Accrued Expense: ₹0 Mil
  • GF Value™: ₹149.77 vs. price of ₹127.91 (14.6% below fair value)
  • GF Score™: 54/100 with 8 warning signs

No single metric tells the full story. See the NSE:VALIANTLAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Valiant Laboratories Business Description

Other Exchanges 543998:India
Address Mulund Goregaon Link Road, 104, Udyog Kshetra, Mulund, MH, IND, 400080
Valiant Laboratories Ltd is an Active Pharmaceutical Ingredient (API)/Bulk Drug manufacturing company with having focus on manufacturing Paracetamol. Paracetamol is one of the widely used analgesics globally and is recommended as the first-line therapy in pain conditions by the World Health Organization. Paracetamol has several applications such as usage in the treatment of headaches, muscle aches, arthritis, backaches, toothaches, colds, and fever. It manufactures Paracetamol in various grades such as IP/BP/EP/USP, as per the pharmacopeia requirements of its customers.
54GF Score

Get the complete analysis for NSE:VALIANTLAB

Accounts Payable & Accrued Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹127.91
Price
₹149.77
GF Value